StockMacro
Menu

Bausch Health Companies

$8.22 +52% in 6 monthsMarket cap $3.1B

BHC on XNYS, Health Care, Bausch Health Companies Inc, job postings

Measures activity, not value. Not investment advice.

Revenue rose 11% to $11.1B over twelve months but net loss reached $841M.

  • GoodFree cash flow reached $1.9B over the last twelve months
  • WatchDebt of $20.6B against $2.5B cash on the latest balance sheet

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

Industry
Pharmaceutical preparations (Health Care)
Employees
20,300
Website
bauschhealth.com
Listed
NYSE, US
Last results
28 Oct 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $2.9B, net income $436.0M.
Quarter to 31 Dec 2021: revenue $2.2B, net income $69.0MQuarter to 31 Dec 2021: revenue $2.2B, net income $69.0MQuarter to 31 Mar 2022: revenue $1.9B, net income -$69.0MQuarter to 31 Mar 2022: revenue $1.9B, net income -$69.0MQuarter to 30 Jun 2022: revenue $2.0B, net income -$145.0MQuarter to 30 Jun 2022: revenue $2.0B, net income -$145.0MQuarter to 30 Sep 2022: revenue $2.0B, net income $399.0MQuarter to 30 Sep 2022: revenue $2.0B, net income $399.0MQuarter to 31 Dec 2022: revenue $2.2B, net income -$410.0MQuarter to 31 Dec 2022: revenue $2.2B, net income -$410.0MQuarter to 31 Mar 2023: revenue $1.9B, net income -$201.0MQuarter to 31 Mar 2023: revenue $1.9B, net income -$201.0MQuarter to 30 Jun 2023: revenue $2.2B, net income $26.0MQuarter to 30 Jun 2023: revenue $2.2B, net income $26.0MQuarter to 30 Sep 2023: revenue $2.2B, net income -$378.0MQuarter to 30 Sep 2023: revenue $2.2B, net income -$378.0MQuarter to 31 Dec 2023: revenue $2.4B, net income -$39.0MQuarter to 31 Dec 2023: revenue $2.4B, net income -$39.0MQuarter to 31 Mar 2024: revenue $2.2B, net income -$64.0MQuarter to 31 Mar 2024: revenue $2.2B, net income -$64.0MQuarter to 30 Jun 2024: revenue $2.4B, net income $10.0MQuarter to 30 Jun 2024: revenue $2.4B, net income $10.0MQuarter to 30 Sep 2024: revenue $2.5B, net income -$85.0MQuarter to 30 Sep 2024: revenue $2.5B, net income -$85.0MQuarter to 31 Dec 2024: revenue $2.6B, net income $93.0MQuarter to 31 Dec 2024: revenue $2.6B, net income $93.0MQuarter to 31 Mar 2025: revenue $2.3B, net income -$58.0MQuarter to 31 Mar 2025: revenue $2.3B, net income -$58.0MQuarter to 30 Jun 2025: revenue $2.5B, net income $148.0MQuarter to 30 Jun 2025: revenue $2.5B, net income $148.0MQuarter to 30 Sep 2025: revenue $2.7B, net income $179.0MQuarter to 30 Sep 2025: revenue $2.7B, net income $179.0MQuarter to 31 Dec 2025: revenue $2.8B, net income -$112.0MQuarter to 31 Dec 2025: revenue $2.8B, net income -$112.0MQuarter to 31 Mar 2026: revenue $2.5B, net income -$1.4BQuarter to 31 Mar 2026: revenue $2.5B, net income -$1.4BQuarter to 30 Jun 2026: revenue $2.9B, net income $258.0MQuarter to 30 Jun 2026: revenue $2.9B, net income $258.0MQuarter to 30 Sep 2026: revenue $2.9B, net income $436.0MQuarter to 30 Sep 2026: revenue $2.9B, net income $436.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $2.9B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$2.9B$436.0M
30 Jun 2026$2.9B$258.0M
31 Mar 2026$2.5B-$1.4B
31 Dec 2025$2.8B-$112.0M
30 Sep 2025$2.7B$179.0M
30 Jun 2025$2.5B$148.0M
31 Mar 2025$2.3B-$58.0M
31 Dec 2024$2.6B$93.0M
30 Sep 2024$2.5B-$85.0M
30 Jun 2024$2.4B$10.0M
31 Mar 2024$2.2B-$64.0M
31 Dec 2023$2.4B-$39.0M
30 Sep 2023$2.2B-$378.0M
30 Jun 2023$2.2B$26.0M
31 Mar 2023$1.9B-$201.0M
31 Dec 2022$2.2B-$410.0M
30 Sep 2022$2.0B$399.0M
30 Jun 2022$2.0B-$145.0M
31 Mar 2022$1.9B-$69.0M
31 Dec 2021$2.2B$69.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $11.1B $10.0B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +11% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$841.0M $362.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.29 $0.97
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 11.2% 18.9% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -7.6% 3.6% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $1.9B $1.1B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $2.5B $1.3B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $20.6B $21.0B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $18.2B $19.7B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 0.28 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.9 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Bausch Health CompaniesBHC (this company) $3.1Bloss0.28+11%-7.6%
Xeris BiopharmaXERS $3.1Bloss8.4+38%-1.8%
Viking TherapeuticsVKTX $3.2Bloss–––
AbCellera BiologicsABCL $3.2Bloss46.6+92%-219%
Acadia PharmaceuticalsACAD $3.0B8.22.5+15%30.1%
Dyne TherapeuticsDYN $2.9Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.6%

228 13F filers vs 220

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

60%

223.6M shares held by 13F filers (30 Sep 2026) of 374.3M outstanding (23 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.0%

7.4M shares sold short (30 Oct 2026) of 374.3M outstanding (23 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.2

7.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-10%

8.2M shares sold short in the report before, 7.4M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

31%

31% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+9.7%

$2.9B vs $2.7B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-27%

$66.0M vs $91.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$610K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

23

23 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

4.6×

23 articles in the last 7 days; its usual week has 5.

Price $8.22 on 20 Nov 2026, +37% over 12 months (12-month range $4.43 to $8.91)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $507K in the last 12 months (the 12 months before: $385.0M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months, -88% on the 12 months before.
Revenue per quarter. Revenue $2.9B in the latest quarter, +9.7% on a year earlier.
Capital spending per quarter. Capital spending $66.0M in the latest quarter, -27% on a year earlier.
Institutional holders (13F filers). 228 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.
Lobbying spend. Lobbying spend: $610K published in the last 12 months, -31% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
1 Jul 20268-K and other filingsDirector or officer change
1 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Apr 2026Lobbying filinglobbying engagement terminated (in-house)
2 Mar 20268-K and other filingsDirector or officer change
2 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 44 vs usual 30.50 (2025-12-31); 1.4x the same period a year earlier
15 Aug 20258-K and other filingsDirector or officer change
15 Aug 20258-K and other filingsA major agreement ended
24 Jul 20258-K and other filingsDirector or officer change
10 Jul 20258-K and other filingsDirector or officer change
15 May 20258-K and other filingsDirector or officer change
15 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Apr 2025Sharp changeLobbying spend jump: lobbying spend jump, 280K vs usual 190K (2025-03-31); 0.9x the same period a year earlier
19 Jul 20248-K and other filingsDirector or officer change
19 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 May 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 82.0M vs usual 49.5M (2024-03-31); 1.7x the same period a year earlier
1 Feb 20248-K and other filingsDirector or officer change
1 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Jan 2024Lobbying filinglobbying engagement terminated (FTI GOVERNMENT AFFAIRS)
17 Oct 2023Lobbying filingnew lobbying registration (CAPITOL HILL CONSULTING GROUP)
29 Sep 20238-K and other filingsCompleted an acquisition or asset sale
18 Sep 20238-K and other filingsDirector or officer change
18 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Mar 20238-K and other filingsDirector or officer change
1 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Oct 2022Lobbying filinglobbying engagement terminated (FOLEY & LARDNER LLP)
26 Sep 2022Lobbying filingnew lobbying registration (FOLEY & LARDNER LLP)
12 Sep 20228-K and other filingsDirector or officer change
23 Jun 20228-K and other filingsDirector or officer change
23 Jun 20228-K and other filingsDirector or officer change
3 Jun 20228-K and other filingsDirector or officer change
31 May 20228-K and other filingsDirector or officer change
31 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Jan 2022Lobbying filinglobbying engagement terminated (PUBLIC STRATEGIES WASHINGTON, INC.)
Insider net buying (open market)
Month from 1 Dec 2021: $1.5M published
Month from 1 Jan 2022: -$87K published
Month from 1 Feb 2022: -$81K published
Month from 1 Mar 2022: -$639K published
Month from 1 Apr 2022: -$35K published
Month from 1 Mar 2023: -$3K published
Month from 1 Sep 2023: -$55K published
Month from 1 Nov 2023: -$327 published
Month from 1 Dec 2023: -$2K published
Month from 1 Mar 2024: -$62K published
Month from 1 Sep 2024: -$83K published
Month from 1 Dec 2024: -$4K published
Month from 1 Jun 2025: $35.9M published
Month from 1 Aug 2025: $333.6M published
Month from 1 Sep 2025: -$98K published
Month from 1 Nov 2025: $15.6M published
Month from 1 Feb 2026: -$50K published
Month from 1 Mar 2026: -$65K published
Month from 1 May 2026: -$133K published
Month from 1 Aug 2026: -$259K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2024: 1 published
Quarter from 1 Oct 2024: 2 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Apr 2025: 3 published
Quarter from 1 Jul 2025: 2 published
Quarter from 1 Oct 2025: 2 published
Quarter from 1 Apr 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $2.2B, -0.8% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $1.9B, -5.4% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $2.0B, -6.3% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $2.0B, -3.1% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $2.2B, -0.1% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $1.9B, +1.4% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $2.2B, +10% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $2.2B, +9.4% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $2.4B, +9.8% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $2.2B, +11% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $2.4B, +11% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $2.5B, +12% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $2.6B, +6.3% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $2.3B, +4.9% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $2.5B, +5.3% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $2.7B, +6.8% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $2.8B, +9.3% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $2.5B, +12% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $2.9B, +13% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $2.9B, +9.7% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $78.0M, -2.5% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $46.0M, -30% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $52.0M, -16% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $54.0M, -14% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $66.0M, -15% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $47.0M, +2.2% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $28.0M, -46% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $42.0M, -22% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $98.0M, +48% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $82.0M, +74% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $78.0M, +179% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $71.0M, +69% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $106.0M, +8.2% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $115.0M, +40% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $99.0M, +27% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $91.0M, +28% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $92.0M, -13% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $109.0M, -5.2% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $77.0M, -22% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $66.0M, -27% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 339; public on 14 Feb 2022
31 Mar 2022 report: 343; public on 16 May 2022
30 Jun 2022 report: 306; public on 15 Aug 2022
30 Sep 2022 report: 259; public on 14 Nov 2022
31 Dec 2022 report: 240; public on 14 Feb 2023
31 Mar 2023 report: 217; public on 15 May 2023
30 Jun 2023 report: 212; public on 14 Aug 2023
30 Sep 2023 report: 202; public on 14 Nov 2023
31 Dec 2023 report: 221; public on 14 Feb 2024
31 Mar 2024 report: 223; public on 15 May 2024
30 Jun 2024 report: 220; public on 14 Aug 2024
30 Sep 2024 report: 201; public on 14 Nov 2024
31 Dec 2024 report: 216; public on 14 Feb 2025
31 Mar 2025 report: 220; public on 15 May 2025
30 Jun 2025 report: 202; public on 14 Aug 2025
30 Sep 2025 report: 204; public on 14 Nov 2025
31 Dec 2025 report: 228; public on 17 Feb 2026
31 Mar 2026 report: 223; public on 15 May 2026
30 Jun 2026 report: 220; public on 14 Aug 2026
30 Sep 2026 report: 228; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $120K published
Quarter from 1 Apr 2022: $240K published
Quarter from 1 Jul 2022: $120K published
Quarter from 1 Oct 2022: $130K published
Quarter from 1 Jan 2023: $130K published
Quarter from 1 Apr 2023: $190K published
Quarter from 1 Jul 2023: $120K published
Quarter from 1 Oct 2023: $180K published
Quarter from 1 Jan 2024: $170K published
Quarter from 1 Apr 2024: $300K published
Quarter from 1 Jul 2024: $190K published
Quarter from 1 Oct 2024: $190K published
Quarter from 1 Jan 2025: $190K published
Quarter from 1 Apr 2025: $310K published
Quarter from 1 Jul 2025: $190K published
Quarter from 1 Oct 2025: $190K published
Quarter from 1 Jan 2026: $190K published
Quarter from 1 Apr 2026: $360K published
Quarter from 1 Jul 2026: $30K published
Quarter from 1 Oct 2026: $30K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $30K (30 Sep 2026), 84% below its normal reading of $190K; higher than 49% of its own history.
  • Insider net buying (open market): Insiders sold a net $507K in the last 12 months (the 12 months before: $385.0M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months, -88% on the 12 months before.
  • Revenue per quarter: Revenue $2.9B in the latest quarter, +9.7% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 75 insider trades

No trades in the last 90 days; the latest was filed 20 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
20 Aug 2026Aimee J. LenarPresident, US PharmaSellplanned in advance (10b5-1)36,827$7.03$259KForm 4
20 May 2026Frank D. LeeDirectorSellplanned in advance (10b5-1)24,456$5.43$133KForm 4
3 Mar 2026Seana CarsonEVP, General CounselSellplanned in advance (10b5-1)11,276$5.78$65KForm 4
27 Feb 2026Seana CarsonEVP, General CounselSellplanned in advance (10b5-1)8,388$5.95$50KForm 4
28 Nov 2025Paulson & Co. Inc.10% ownerBuy2,500,000$6.25$15.6MForm 4
8 Sep 2025Seana CarsonEVP, General CounselSellplanned in advance (10b5-1)13,370$7.31$98KForm 4
22 Aug 2025Frank D. LeeDirectorSell15,912$7.66$122KForm 4
14 Aug 2025John PaulsonDirectorBuy34,721,118$9.00$312.5MForm 4

228 institutions reported shares at the end of Q3 2026, 60% of the shares outstanding; 38 opened a position, 27 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Paulson & Co. Inc.73.3M19.6%$427.1MNo change
Goldentree Asset Management LP34.7M9.26%$201.9MNo change
Royal Bank of Canada9.2M2.45%$53.6M-1.6M-15%
Goldman Sachs Group Inc7.7M2.07%$45.2M+1.5M+24%
Vanguard Capital Management LLC7.4M1.99%$43.4M-21K-0.3%
Two Sigma Investments, LP7.4M1.98%$43.2M+5.3M+247%
Acadian Asset Management LLC7.2M1.93%+1.8M+32%
MFN Partners Management, LP6.0M1.60%$35.0MNo change
Gendell Jeffrey L4.2M1.12%$24.4M+152K+3.8%
D. E. Shaw & Co., Inc.3.5M0.94%$20.5M+819K+30%

Company events

All 80 company events

In 12 months: 2 major agreements, 2 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
1 Jul 2026Director or officer change8-K
2 Mar 2026Director or officer change8-K
2 Jan 2026Signed a major agreementSame filing: took on new debt8-K
29 Dec 2025Signed a major agreementSame filing: took on new debt8-K
15 Aug 2025Director or officer change; A major agreement ended8-K
24 Jul 2025Director or officer change8-K
10 Jul 2025Director or officer change8-K
27 Jun 2025Signed a major agreementSame filing: took on new debt8-K

Reported lobbying spend: $30K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Mar 2026EndedBausch Health Companiesits own lobbyistsGeneral issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures ActHealth issuesFiling
1 Sep 2023NewCapitol Hill Consulting Groupfor Bausch HealthMedicare and Medicaid payment policies.Health issuesFiling
1 Jul 2023EndedFti Government Affairsfor Bausch Health Companies Inc.Not statedFiling
26 Sep 2022EndedFoley & Lardner LLPfor Bausch Health Companies, Inc.Not statedFiling
10 Aug 2022NewFoley & Lardner LLPfor Bausch Health Companies, Inc.HCR (Patent issue w/ Xifanan)Health issuesFiling
31 Dec 2021EndedPublic Strategies Washington, Inc.for Bausch Health Companies, Inc.Not statedFiling
1 Jan 2021NewPublic Strategies Washington, Inc.for Bausch Health Companies, Inc.Proposals impacting the prescription drug industry, including issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally. Issues relating to biologics and biosimilars in Medicare and generally.Medicare/Medicaid, Health issuesFiling
31 Mar 2020EndedKing & Spalding LLPfor Bausch Health Companies Inc F/K/A Valeant Pharmaceuticals International IncImplementation of Drug Quality and Security Act (DQSA) of 2013Health issuesFiling

Layoff notices

All 1 layoff notices

No notice in 12 months; the latest is dated 1 Dec 2006. State WARN notices.

NoticeSiteWorkersJobs endSource
1 Dec 2006BIOVAILBRIDGEWATER, NJ6011 Feb 2007Notice

The 5 newest of 271 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

25 Feb 2020confirmed

Confirmed across sources Attention and Insiders and Lobbying and Short interest and volume

Bausch Health Companies (BHC): had 19.8M shares sold short in the 31 Jan 2020 report, 1.8× the same report last year; it also drew 6,767 Wikipedia page views in the week of 17 Feb 2020, 1.5× the same week last year; it also had 3 insiders buy $285K of its shares on the open market within 30 days (3 filings); and it reported $380K of lobbying spend for the quarter ended 31 Mar 2020, 1.1× the same quarter last year. Four unrelated kinds of activity within 105 days.

  • Short interest and volume: Short interest spike, became public on 28 Jan 2020
  • Short interest and volume: Short interest spike, became public on 12 Feb 2020
  • Attention: Wikipedia attention spike, became public on 25 Feb 2020
  • Short interest and volume: Short interest spike, became public on 27 Feb 2020
  • Insiders: Clustered insider buying, became public on 12 Mar 2020
  • Short interest and volume: Short interest spike, became public on 11 Mar 2020
  • Short interest and volume: Short interest spike, became public on 25 Mar 2020
  • Lobbying: Lobbying spend jump, became public on 8 Apr 2020
  • Short interest and volume: Short interest spike, became public on 10 Apr 2020
  • Short interest and volume: Short interest spike, became public on 25 Apr 2020
  • Short interest and volume: Short interest spike, became public on 12 May 2020
2019-01-31: 10.7M2019-02-15: 9.3M2019-02-28: 10.9M2019-03-15: 9.6M2019-03-29: 9.0M2019-04-15: 9.0M2019-04-30: 10.9M2019-05-15: 10.7M2019-05-31: 11.3M2019-06-14: 11.0M2019-06-28: 11.0M2019-07-15: 10.1M2019-07-31: 10.0M2019-08-15: 10.3M2019-08-30: 10.2M2019-09-13: 10.1M2019-09-30: 9.1M2019-10-15: 11.9M2019-10-31: 9.8M2019-11-15: 10.7M2019-11-29: 12.2M2019-12-13: 15.0M2019-12-31: 18.1M2020-01-15: 18.2M2020-01-31: 19.8M
The 31 Jan 2020 report against the 24 reports before it. this reportearliernormal: 10.7M
See the evidence (11 changes)

Short interest and volume: Short interest spike became public on 28 Jan 2020

Bausch Health Companies had 18.2M shares sold short in the 15 Jan 2020 report, 1.7× the same report last year.

This period
18.2M (the 15 Jan 2020 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
598K
How far from its usual level
+7.1
Same report last year
10.7M
History used
533 days
2019-01-15: 10.7M2019-01-31: 10.7M2019-02-15: 9.3M2019-02-28: 10.9M2019-03-15: 9.6M2019-03-29: 9.0M2019-04-15: 9.0M2019-04-30: 10.9M2019-05-15: 10.7M2019-05-31: 11.3M2019-06-14: 11.0M2019-06-28: 11.0M2019-07-15: 10.1M2019-07-31: 10.0M2019-08-15: 10.3M2019-08-30: 10.2M2019-09-13: 10.1M2019-09-30: 9.1M2019-10-15: 11.9M2019-10-31: 9.8M2019-11-15: 10.7M2019-11-29: 12.2M2019-12-13: 15.0M2019-12-31: 18.1M2020-01-15: 18.2M
the 15 Jan 2020 report24 earlier reportsnormal: 10.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Feb 2020

Bausch Health Companies had 19.8M shares sold short in the 31 Jan 2020 report, 1.8× the same report last year.

This period
19.8M (the 31 Jan 2020 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
665K
How far from its usual level
+8.5
Same report last year
10.7M
History used
549 days
2019-01-31: 10.7M2019-02-15: 9.3M2019-02-28: 10.9M2019-03-15: 9.6M2019-03-29: 9.0M2019-04-15: 9.0M2019-04-30: 10.9M2019-05-15: 10.7M2019-05-31: 11.3M2019-06-14: 11.0M2019-06-28: 11.0M2019-07-15: 10.1M2019-07-31: 10.0M2019-08-15: 10.3M2019-08-30: 10.2M2019-09-13: 10.1M2019-09-30: 9.1M2019-10-15: 11.9M2019-10-31: 9.8M2019-11-15: 10.7M2019-11-29: 12.2M2019-12-13: 15.0M2019-12-31: 18.1M2020-01-15: 18.2M2020-01-31: 19.8M
the 31 Jan 2020 report24 earlier reportsnormal: 10.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Attention: Wikipedia attention spike became public on 25 Feb 2020

Bausch Health Companies drew 6,767 Wikipedia page views in the week of 17 Feb 2020, 1.5× the same week last year.

This period
6,767 (the week of 17 Feb 2020)
Normal week (median of 26 earlier)
3,438
Typical spread (median absolute deviation)
306
How far from its usual level
+7.3
Same week last year
4,586
History used
418 days
2019-08-19: 2,9462019-08-26: 2,9142019-09-02: 2,7892019-09-09: 2,9742019-09-16: 2,7592019-09-23: 5,5682019-09-30: 3,7912019-10-07: 3,3392019-10-14: 2,9932019-10-21: 3,1632019-10-28: 3,5282019-11-04: 3,5872019-11-11: 3,0472019-11-18: 3,5842019-11-25: 3,2462019-12-02: 3,4002019-12-09: 3,2572019-12-16: 3,4772019-12-23: 3,1012019-12-30: 3,5982020-01-06: 3,6032020-01-13: 3,6202020-01-20: 3,8782020-01-27: 3,5682020-02-03: 3,8672020-02-10: 4,9252020-02-17: 6,767
the week of 17 Feb 202026 earlier weeksnormal: 3,438

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Short interest and volume: Short interest spike became public on 27 Feb 2020

Bausch Health Companies had 20.2M shares sold short in the 14 Feb 2020 report, 2.2× the same report last year.

This period
20.2M (the 14 Feb 2020 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
834K
How far from its usual level
+7.6
Same report last year
9.3M
History used
563 days
2019-02-15: 9.3M2019-02-28: 10.9M2019-03-15: 9.6M2019-03-29: 9.0M2019-04-15: 9.0M2019-04-30: 10.9M2019-05-15: 10.7M2019-05-31: 11.3M2019-06-14: 11.0M2019-06-28: 11.0M2019-07-15: 10.1M2019-07-31: 10.0M2019-08-15: 10.3M2019-08-30: 10.2M2019-09-13: 10.1M2019-09-30: 9.1M2019-10-15: 11.9M2019-10-31: 9.8M2019-11-15: 10.7M2019-11-29: 12.2M2019-12-13: 15.0M2019-12-31: 18.1M2020-01-15: 18.2M2020-01-31: 19.8M2020-02-14: 20.2M
the 14 Feb 2020 report24 earlier reportsnormal: 10.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Insiders: Clustered insider buying became public on 12 Mar 2020

Bausch Health Companies had 3 insiders buy $285K of its shares on the open market within 30 days (3 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$285K
Window
11 Feb 2020 to 12 Mar 2020

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 11 Mar 2020

Bausch Health Companies had 20.0M shares sold short in the 28 Feb 2020 report, 1.8× the same report last year.

This period
20.0M (the 28 Feb 2020 report)
Normal report (median of 24 earlier)
10.8M
Typical spread (median absolute deviation)
945K
How far from its usual level
+6.6
Same report last year
10.9M
History used
577 days
2019-02-28: 10.9M2019-03-15: 9.6M2019-03-29: 9.0M2019-04-15: 9.0M2019-04-30: 10.9M2019-05-15: 10.7M2019-05-31: 11.3M2019-06-14: 11.0M2019-06-28: 11.0M2019-07-15: 10.1M2019-07-31: 10.0M2019-08-15: 10.3M2019-08-30: 10.2M2019-09-13: 10.1M2019-09-30: 9.1M2019-10-15: 11.9M2019-10-31: 9.8M2019-11-15: 10.7M2019-11-29: 12.2M2019-12-13: 15.0M2019-12-31: 18.1M2020-01-15: 18.2M2020-01-31: 19.8M2020-02-14: 20.2M2020-02-28: 20.0M
the 28 Feb 2020 report24 earlier reportsnormal: 10.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Mar 2020

Bausch Health Companies had 23.0M shares sold short in the 13 Mar 2020 report, 2.4× the same report last year.

This period
23.0M (the 13 Mar 2020 report)
Normal report (median of 24 earlier)
10.8M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+7.7
Same report last year
9.6M
History used
591 days
2019-03-15: 9.6M2019-03-29: 9.0M2019-04-15: 9.0M2019-04-30: 10.9M2019-05-15: 10.7M2019-05-31: 11.3M2019-06-14: 11.0M2019-06-28: 11.0M2019-07-15: 10.1M2019-07-31: 10.0M2019-08-15: 10.3M2019-08-30: 10.2M2019-09-13: 10.1M2019-09-30: 9.1M2019-10-15: 11.9M2019-10-31: 9.8M2019-11-15: 10.7M2019-11-29: 12.2M2019-12-13: 15.0M2019-12-31: 18.1M2020-01-15: 18.2M2020-01-31: 19.8M2020-02-14: 20.2M2020-02-28: 20.0M2020-03-13: 23.0M
the 13 Mar 2020 report24 earlier reportsnormal: 10.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying spend jump became public on 8 Apr 2020

Bausch Health Companies reported $380K of lobbying spend for the quarter ended 31 Mar 2020, 1.1× the same quarter last year.

This period
$380K (the quarter ended 31 Mar 2020)
Normal quarter (median of 8 earlier)
$159K
Typical spread (median absolute deviation)
$36K
How far from its usual level
+4.1
Same quarter last year
$350K
History used
3,288 days
2018-03-31: $30K2018-06-30: $10K2018-09-30: $200K2018-12-31: $190K2019-03-31: $350K2019-06-30: $158K2019-09-30: $158K2019-12-31: $160K2020-03-31: $380K
the quarter ended 31 Mar 20208 earlier quartersnormal: $159K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Short interest and volume: Short interest spike became public on 10 Apr 2020

Bausch Health Companies had 23.5M shares sold short in the 31 Mar 2020 report, 2.6× the same report last year.

This period
23.5M (the 31 Mar 2020 report)
Normal report (median of 24 earlier)
11.0M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+7.8
Same report last year
9.0M
History used
609 days
2019-03-29: 9.0M2019-04-15: 9.0M2019-04-30: 10.9M2019-05-15: 10.7M2019-05-31: 11.3M2019-06-14: 11.0M2019-06-28: 11.0M2019-07-15: 10.1M2019-07-31: 10.0M2019-08-15: 10.3M2019-08-30: 10.2M2019-09-13: 10.1M2019-09-30: 9.1M2019-10-15: 11.9M2019-10-31: 9.8M2019-11-15: 10.7M2019-11-29: 12.2M2019-12-13: 15.0M2019-12-31: 18.1M2020-01-15: 18.2M2020-01-31: 19.8M2020-02-14: 20.2M2020-02-28: 20.0M2020-03-13: 23.0M2020-03-31: 23.5M
the 31 Mar 2020 report24 earlier reportsnormal: 11.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Apr 2020

Bausch Health Companies had 21.3M shares sold short in the 15 Apr 2020 report, 2.4× the same report last year.

This period
21.3M (the 15 Apr 2020 report)
Normal report (median of 24 earlier)
11.0M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+6.3
Same report last year
9.0M
History used
624 days
2019-04-15: 9.0M2019-04-30: 10.9M2019-05-15: 10.7M2019-05-31: 11.3M2019-06-14: 11.0M2019-06-28: 11.0M2019-07-15: 10.1M2019-07-31: 10.0M2019-08-15: 10.3M2019-08-30: 10.2M2019-09-13: 10.1M2019-09-30: 9.1M2019-10-15: 11.9M2019-10-31: 9.8M2019-11-15: 10.7M2019-11-29: 12.2M2019-12-13: 15.0M2019-12-31: 18.1M2020-01-15: 18.2M2020-01-31: 19.8M2020-02-14: 20.2M2020-02-28: 20.0M2020-03-13: 23.0M2020-03-31: 23.5M2020-04-15: 21.3M
the 15 Apr 2020 report24 earlier reportsnormal: 11.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 May 2020

Bausch Health Companies had 19.6M shares sold short in the 30 Apr 2020 report, 1.8× the same report last year.

This period
19.6M (the 30 Apr 2020 report)
Normal report (median of 24 earlier)
11.2M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+5.1
Same report last year
10.9M
History used
639 days
2019-04-30: 10.9M2019-05-15: 10.7M2019-05-31: 11.3M2019-06-14: 11.0M2019-06-28: 11.0M2019-07-15: 10.1M2019-07-31: 10.0M2019-08-15: 10.3M2019-08-30: 10.2M2019-09-13: 10.1M2019-09-30: 9.1M2019-10-15: 11.9M2019-10-31: 9.8M2019-11-15: 10.7M2019-11-29: 12.2M2019-12-13: 15.0M2019-12-31: 18.1M2020-01-15: 18.2M2020-01-31: 19.8M2020-02-14: 20.2M2020-02-28: 20.0M2020-03-13: 23.0M2020-03-31: 23.5M2020-04-15: 21.3M2020-04-30: 19.6M
the 30 Apr 2020 report24 earlier reportsnormal: 11.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 1 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 1 Jul 2026Filings record

    Director or officer change

  3. 16 Apr 2026Lobbying record

    BAUSCH HEALTH COMPANIES: lobbying engagement terminated (in-house) (dated 31 Mar 2026)

  4. 2 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 2 Mar 2026Filings record

    Director or officer change

  6. 17 Feb 2026Institutional holdings change

    saw 44 13F filers open a new position in the quarter ended 31 Dec 2025, 1.4× the same quarter last year.

    Same quarter last year: 31; its normal quarter is 30.5.

    See the evidence
    This period
    44 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    30.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +4.4
    Same quarter last year
    31
    History used
    2,741 days
    2023-12-31: 322024-03-31: 292024-06-30: 362024-09-30: 252024-12-31: 312025-03-31: 332025-06-30: 242025-09-30: 302025-12-31: 44
    the quarter ended 31 Dec 20258 earlier quartersnormal: 30.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  7. 29 Nov 2025Insiders record

    PAULSON & CO. INC. (ten percent owner) bought 2,500,000 shares of BHC ($15.6M) (dated 28 Nov 2025)

  8. 15 Aug 2025Filings record

    Director or officer change

  9. 15 Aug 2025Filings record

    A major agreement ended

  10. 15 Aug 2025Insiders record

    Paulson John (director) bought 34,721,118 shares of BHC ($312.5M) (dated 14 Aug 2025)

  11. 14 Aug 2025Insiders record

    Paulson John (director) bought 3,243,049 shares of BHC ($21.3M) (dated 13 Aug 2025)

  12. 24 Jul 2025Filings record

    Director or officer change

  13. 10 Jul 2025Filings record

    Director or officer change

  14. 18 Jun 2025Insiders record

    Paulson John (director) bought 3,564,059 shares of BHC ($21.2M) (dated 17 Jun 2025)

  15. 13 Jun 2025Insiders record

    Paulson John (director) bought 2,788,608 shares of BHC ($14.7M) (dated 12 Jun 2025)

  16. 15 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 15 May 2025Filings record

    Director or officer change

  18. 9 Apr 2025Lobbying change

    reported $280K of lobbying spend for the quarter ended 31 Mar 2025, 6.7% below the same quarter last year.

    Same quarter last year: $300K; its normal quarter is $190K.

    See the evidence
    This period
    $280K (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $190K
    Typical spread (median absolute deviation)
    $5K
    How far from its usual level
    +4.5
    Same quarter last year
    $300K
    History used
    5,844 days
    2023-03-31: $190K2023-06-30: $120K2023-09-30: $180K2023-12-31: $170K2024-03-31: $300K2024-06-30: $190K2024-09-30: $190K2024-12-31: $190K2025-03-31: $280K
    the quarter ended 31 Mar 20258 earlier quartersnormal: $190K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  19. 19 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 19 Jul 2024Filings record

    Director or officer change

  21. 7 May 2024Financials change

    spent $82.0M on capital projects in the quarter ended 31 Mar 2024, 1.7× the same quarter last year.

    Same quarter last year: $47.0M; its normal quarter is $49.5M.

    See the evidence
    This period
    $82.0M (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $49.5M
    Typical spread (median absolute deviation)
    $6.0M
    How far from its usual level
    +3.7
    Same quarter last year
    $47.0M
    History used
    5,388 days
    2022-03-31: $46.0M2022-06-30: $52.0M2022-09-30: $54.0M2022-12-31: $66.0M2023-03-31: $47.0M2023-06-30: $28.0M2023-09-30: $42.0M2023-12-31: $98.0M2024-03-31: $82.0M
    the quarter ended 31 Mar 20248 earlier quartersnormal: $49.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  22. 1 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 1 Feb 2024Filings record

    Director or officer change

  24. 17 Jan 2024Lobbying record

    BAUSCH HEALTH COMPANIES INC.: lobbying engagement terminated (FTI GOVERNMENT AFFAIRS) (dated 1 Jul 2023)

  25. 17 Oct 2023Lobbying record

    BAUSCH HEALTH: new lobbying registration (CAPITOL HILL CONSULTING GROUP) (dated 1 Sep 2023)

  26. 29 Sep 2023Filings record

    Completed an acquisition or asset sale

  27. 18 Sep 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 18 Sep 2023Filings record

    Director or officer change

  29. 1 Mar 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 1 Mar 2023Filings record

    Director or officer change

  31. 7 Oct 2022Lobbying record

    BAUSCH HEALTH COMPANIES, INC.: lobbying engagement terminated (FOLEY & LARDNER LLP) (dated 26 Sep 2022)

  32. 26 Sep 2022Lobbying record

    BAUSCH HEALTH COMPANIES, INC.: new lobbying registration (FOLEY & LARDNER LLP) (dated 10 Aug 2022)

  33. 12 Sep 2022Filings record

    Director or officer change

  34. 23 Jun 2022Filings record

    Director or officer change

  35. 23 Jun 2022Filings record

    Director or officer change

  36. 3 Jun 2022Filings record

    Director or officer change

  37. 31 May 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 31 May 2022Filings record

    Director or officer change

  39. 19 Jan 2022Lobbying record

    BAUSCH HEALTH COMPANIES, INC.: lobbying engagement terminated (PUBLIC STRATEGIES WASHINGTON, INC.) (dated 31 Dec 2021)

  40. 3 Dec 2021Insiders record

    Miller Steven D (director) bought 60,000 shares of BHC ($1.5M) (dated 2 Dec 2021)

Showing the newest 40 of 128 entries; narrow the window or the kind of data to see older ones.

Not listed: 238 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000885590
Ticker
BHC
Domain
bauschhealth.com
Employer name
Bausch Health, Bausch Health US, LLC, BIOVAIL (3 unverified)
Fein
33-0949894 (1 unverified)
Hq location
A8|QUEBEC|H7L 4 (1 unverified)
Lobbying client
bausch health, bausch health companies, bausch health companies inc f k a valeant pharmaceuticals international, valeant pharmaceuticals
Name
12279967 Canada Ltd, 12283778 Canada Ltd, 1261229 B.C. Ltd, 1375209 B.C. Ltd and 151 more
Wikidata
Q1700871
Wikipedia
Bausch Health
  • DOL H-1B labor condition applications and PERM certifications67 data points17 Jun 2024 to 9 Feb 2026
  • Federal lobbying disclosures (LDA)13 records, 218 data points30 Jun 2005 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 306 data points30 Jun 2018 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)245 records6 Jan 2016 to 28 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1108 data points31 Dec 2007 to 23 Oct 2026
  • SEC Form 4 insider transactions75 records, 252 data points13 Jun 2016 to 20 Aug 2026
  • FINRA short interest (twice monthly)594 data points31 Jul 2018 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • WARN layoff notices (state labor agencies)1 record, 3 data points27 Nov 2006 to 1 Dec 2006
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026